1.15
+0.01999998(+1.77%)
Currency In USD
| Previous Close | 1.13 |
| Open | 1.16 |
| Day High | 1.17 |
| Day Low | 1.07 |
| 52-Week High | 9.79 |
| 52-Week Low | 0.97 |
| Volume | 680,131 |
| Average Volume | 2.9M |
| Market Cap | 12.38M |
| PE | -0.53 |
| EPS | -2.15 |
| Moving Average 50 Days | 1.8 |
| Moving Average 200 Days | 1.96 |
| Change | 0.02 |
If you invested $1000 in Phio Pharmaceuticals Corp. (PHIO) 10 years ago, it would be worth $0 as of December 10, 2025 at a share price of $1.15. Whereas If you bought $1000 worth of Phio Pharmaceuticals Corp. (PHIO) shares 5 years ago, it would be worth $3.21 as of December 10, 2025 at a share price of $1.15.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762
Newsfile
Nov 25, 2025 4:30 PM GMT
King of Prussia, Pennsylvania--(Newsfile Corp. - November 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to el
Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress
Newsfile
Nov 17, 2025 1:45 PM GMT
Presenting INTASYL siRNA Drug TechnologyKing of Prussia, Pennsylvania--(Newsfile Corp. - November 17, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary
Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Newsfile
Nov 13, 2025 9:15 PM GMT
Clinical Trial has Advanced to Fifth and Final Cohort at Maximum Dose of INSTASYL PH-762 in Skin Cancer Trial Positive Pathology Results at Maximum Dose: 100% Tumor Clearance (Complete Response) in One Patient, Greater than 90% (Near Complete Respons